BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-29 08:15 |
Regulatory News Service
Kina godkänner intravenös underhållsbehandling med Leqembi®
|
Swedish | 235.6 KB | ||
| 2025-09-29 08:15 |
Regulatory News Service
Leqembi® approved for IV maintenance treatment in China
|
English | 229.9 KB | ||
| 2025-09-24 08:40 |
Regulatory News Service
Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
|
English | 237.4 KB | ||
| 2025-09-24 08:40 |
Regulatory News Service
Australien godkänner Leqembi® för behandling av tidig Alzheimers sjukdom
|
Swedish | 225.9 KB | ||
| 2025-09-03 17:35 |
Major Shareholding Notification
BioArctics grundare har för avsikt att sälja en mindre del av sitt aktieinnehav
|
Swedish | 182.9 KB | ||
| 2025-09-03 17:35 |
Major Shareholding Notification
BioArctic’s founders intend to divest minor part of their shareholding
|
English | 179.0 KB | ||
| 2025-09-03 01:30 |
Regulatory News Service
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as …
|
English | 211.3 KB | ||
| 2025-09-03 01:30 |
Regulatory News Service
Stegvis ansökningsprocess påbörjad för marknadsgodkännande i USA av Leqembi® Iq…
|
Swedish | 253.3 KB | ||
| 2025-09-01 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025
|
English | 196.1 KB | ||
| 2025-09-01 18:30 |
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i BioArctic AB (publ) per den 29 augusti 2025
|
Swedish | 209.2 KB | ||
| 2025-08-29 23:56 |
Regulatory News Service
Amerikanska läkemedelsverket godkänner subkutan underhållsbehandling med Leqemb…
|
Swedish | 251.3 KB | ||
| 2025-08-29 23:55 |
Regulatory News Service
US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for m…
|
English | 212.0 KB | ||
| 2025-08-28 08:00 |
Interim Report
|
Swedish | 1.8 MB | ||
| 2025-08-28 08:00 |
Interim Report
|
English | 1.6 MB | ||
| 2025-08-26 07:05 |
M&A Activity
BioArctic och Novartis ingår options-, samarbets- och licensavtal som nyttjar B…
|
Swedish | 201.1 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2020-05-26 | Gunilla Osswald | Other | Sell | 25,000 | 1,763,275.00 SEK |
| 2020-05-26 | Pär Lars Gellerfors | Other | Sell | 3,705 | 98,812.35 SEK |
| 2020-05-26 | Pär Lars Gellerfors | Other | Sell | 5,685 | 151,618.95 SEK |
| 2020-05-26 | Pär Lars Gellerfors | Other | Sell | 26,505 | 706,888.35 SEK |
| 2020-05-26 | Pär Lars Gellerfors | Other | Sell | 3,300 | 88,011.00 SEK |
| 2020-05-26 | Pär Lars Gellerfors | Other | Sell | 10,905 | 290,836.35 SEK |
| 2020-05-26 | Pär Lars Gellerfors | Other | Sell | 2,730 | 72,809.10 SEK |
| 2020-05-26 | Mikael Smedeby | Other | Other | 16,365 | 436,454.55 SEK |
| 2020-05-26 | Mikael Smedeby | Other | Other | 10,905 | 290,836.35 SEK |
| 2020-05-26 | Jan Mattsson | Other | Other | 5,565 | 148,418.55 SEK |
